Post covid brain disorders

42%increased chance of developing a neuro problem after covid, equating to 7% of those infected. Dr. Al-Aly Overall, COVID-19 has contributed to more than 40 million new cases of neurological disorders worldwide Long-term neurologic outcomes of COVID-19 https://www.nature.com/articles/s41591-022-02001-z https://newatlas.com/health-wellbeing/mild-covid-risk-brain-neurological-problems/ https://medicine.wustl.edu/news/covid-19-infections-increase-risk-of-long-term-brain-problems/ Comprehensive evaluation of postacute neurologic sequelae at 1 year National healthcare databases of the US Department of Veterans Affairs Covid cohort = 154,068 (nonhospitalized, hospitalized and admitted to intensive care) Contemporary controls = 5,638,795 Historical controls = 5,859,621 (2017 data) Average age of 61 Estimate risks and burdens of incident neurologic disorders at 12 months following acute SARS-CoV-2 infection Longitudinal observational study design March 2020 through January 2021 (predates delta, omicron and other COVID variants) Results In the postacute phase of COVID-19, there was increased risk of an array of incident neurologic sequelae Ischemic and hemorrhagic stroke TIA Cognition and memory disorders Peripheral nervous system disorders Episodic disorders (e.g. migraine, seizures) Extrapyramidal and movement disorders Mental health disorders, (anxiety depression psychosis) Musculoskeletal disorders Sensory disorders Guillain–Barré syndrome Encephalitis or encephalopathy Headaches Hazard ratio of any neurologic sequela 1.42 (1.38 to 1.47) Burden 70.69 (63.54 to 78.01) per 1,000 persons at 12 months Or, 7.069% The risks and burdens were elevated even in people who did not require hospitalization during acute COVID-19 Risks and burdens increased according to the severity of the acute infection, from nonhospitalized to hospitalized to intensive care Dizzynes Taken together, our results provide evidence of increased risk of long-term neurologic disorders in people who had COVID-19. Incident neurologic outcomes in COVID-19 versus contemporary control Cerebrovascular disorders (at 12 months) Ischemic stroke HR 1.50, burden 3.40 per 1,000 Transient ischemic attacks HR 1.62, burden 2.03 Hemorrhagic stroke HR 2.19, burden 0.21 Cerebral venous thrombosis HR 2.69, burden 0.05 Composite of these cerebrovascular outcomes were HR 1.56, burden 4.92 Cognition and memory Risks of memory problems HR 1.77, burden 10.07 Alzheimer’s disease HR 2.03, burden 1.65 Composite of these cognition and memory outcomes were HR 1.80, Burden 10.35 Disorders of peripheral nerves Peripheral neuropathy HR 1.34, burden 5.64 Paresthesia HR 1.32, burden 2.89 Dysautonomia HR 1.30, burden 1.60 Bell’s palsy HR 1.48, burden 0.32 Composite of these disorders of peripheral nerves were HR 1.34, burden 8.64 Episodic disorders Migraine, epilepsy and seizures, headache disorders Composite of these episodic disorders were HR 1.32, burden 4.75 Extrapyramidal and movement disorders Abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus Composite of these extrapyramidal and movement disorders were HR 1.42, burden 3.98 Mental health disorders Major depressive disorders, stress and adjustment disorders, anxiety disorders, psychotic disorders Composite of these mental health disorders were HR 1.43, burden 25.00 Musculoskeletal disorders Joint pain, myalgia, myopathy Composite of these musculoskeletal disorders were HR 1.45, burden 40.09 Sensory disorders Hearing abnormalities, tinnitus, vision abnormalities, loss of smell, loss of taste Composite of these sensory disorders were HR 1.25, burden 17.03 Other neurologic or related disorders Dizziness, somnolence, Guillain–Barré syndrome, encephalitis or encephalopathy, transverse myelitis Composite of these other neurologic or related Learn more about your ad choices. Visit megaphone.fm/adchoices